The significant global economic burden of bronchiectasis: a pending matter-Reference-Cited by-同舟云学术

The significant global economic burden of bronchiectasis: a pending matter

Published:2019-02 Issue:2 Volume:53 Page:1802392
ISSN:0903-1936
Container-title:European Respiratory Journal
language:en
Short-container-title:Eur Respir J

Author:

Guan Wei-jie,Han Xiao-rong,de la Rosa-Carrillo David^ORCID,Martinez-Garcia Miguel Angel

Funder

National Natural Science Foundation of China

Guangdong Province Universities and Colleges Pearl River Scholar Funded Scheme 2017

Pearl River S&T Nova Program of Guangzhou

Publisher

European Respiratory Society (ERS)

Subject

Pulmonary and Respiratory Medicine

Reference23 articles.

1. European Medicines Agency. Human Regulatory. Orphan Designation: Overview. www.ema.europa.eu/en/human-regulatory/overview/orphan-designation-overview Date last updated: March 15, 2018. Date last accessed: December 14, 2018.

2. Bronchiectasis in Germany: a population-based estimation of disease prevalence

3. Prevalence and incidence of bronchiectasis in Catalonia, Spain: a population-based study;Monteagudo;Respir Med,2016

4. Changes in the incidence, prevalence and mortality of bronchiectasis in the UK from 2004 to 2013: a population-based cohort study

5. Prevalence and incidence of noncystic fibrosis bronchiectasis among US adults in 2013;Weycker;Chron Respir Dis,2017

Cited by 20 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Physiotherapy-led, community-based airway clearance services for people with chronic lung conditions: a retrospective descriptive evaluation of an existing model of care;BMC Health Services Research;2024-01-18

2. Lung microbiome: new insights into the pathogenesis of respiratory diseases;Signal Transduction and Targeted Therapy;2024-01-17

3. Healthcare costs and resource utilisation in bronchiectasis, asthma and COPD;ERJ Open Research;2023-06-01

4. Advances in pharmacotherapy for bronchiectasis in adults;Expert Opinion on Pharmacotherapy;2023-05-09

5. A Phase 2 randomised study to establish efficacy, safety and dosing of a novel oral cathepsin C inhibitor, BI 1291583, in adults with bronchiectasis: Airleaf;ERJ Open Research;2023-05